MX2010002993A - Uso de clec1b para la determinacion de riesgo cardiovascular y trombotico. - Google Patents

Uso de clec1b para la determinacion de riesgo cardiovascular y trombotico.

Info

Publication number
MX2010002993A
MX2010002993A MX2010002993A MX2010002993A MX2010002993A MX 2010002993 A MX2010002993 A MX 2010002993A MX 2010002993 A MX2010002993 A MX 2010002993A MX 2010002993 A MX2010002993 A MX 2010002993A MX 2010002993 A MX2010002993 A MX 2010002993A
Authority
MX
Mexico
Prior art keywords
cardiovascular
clec1b
determination
thrombotic disorders
thrombotic risk
Prior art date
Application number
MX2010002993A
Other languages
English (en)
Inventor
Matthias Herrmann
Detlef Kozian
Peter Wonerow
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2010002993A publication Critical patent/MX2010002993A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El uso del polimorfismo de un solo nuc!e?tido (SNP) del gen CLEC1B para la identificaci?n de trastornos cardiovasculares y/o tromb?ticos o de un aumento del riesgo de desarrollar trastornos cardiovasculares y/o tromb?ticos en una muestra biol?gica extra?da de un individuo bajo examen; el uso de CLEC1B para identificar sustancias activas para prevenir y/o tratar trastornos cardiovasculares y/o tromb?ticos, m?todos para ello.
MX2010002993A 2007-09-24 2008-09-13 Uso de clec1b para la determinacion de riesgo cardiovascular y trombotico. MX2010002993A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07291134A EP2048243A1 (en) 2007-09-24 2007-09-24 Use of clec1B for the determination of cardiovascular and thrombotic risk
PCT/EP2008/007593 WO2009040002A1 (en) 2007-09-24 2008-09-13 Use of clec1b for the determination of cardiovascular and thrombotic risk

Publications (1)

Publication Number Publication Date
MX2010002993A true MX2010002993A (es) 2010-04-01

Family

ID=38765869

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002993A MX2010002993A (es) 2007-09-24 2008-09-13 Uso de clec1b para la determinacion de riesgo cardiovascular y trombotico.

Country Status (15)

Country Link
US (1) US20100311053A1 (es)
EP (3) EP2048243A1 (es)
JP (1) JP2010539891A (es)
KR (1) KR20100059897A (es)
CN (1) CN101809168A (es)
AR (1) AR068529A1 (es)
AT (1) ATE547706T1 (es)
AU (1) AU2008303866A1 (es)
BR (1) BRPI0817944A2 (es)
CA (1) CA2700219A1 (es)
IL (1) IL204557A0 (es)
MX (1) MX2010002993A (es)
SG (1) SG184704A1 (es)
TW (1) TW200934877A (es)
WO (1) WO2009040002A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269597A1 (en) * 2009-06-22 2011-01-05 CSL Behring GmbH CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis
EP2710149B1 (en) * 2011-05-14 2017-03-08 Royal College of Surgeons in Ireland Identification of thrombosis or bleeding risk in an individual with and without anti-platelet therapy
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
EP2592422A1 (en) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
CN105112554B (zh) * 2015-09-28 2019-03-01 北京泱深生物信息技术有限公司 Clec1b基因在胆管癌诊断和治疗中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
WO2006115295A1 (en) * 2005-04-25 2006-11-02 University Of Yamanashi Compositions and methods for treating hemostasis disorders associated with clec-2 signal transduction
JP2007070359A (ja) * 2005-09-06 2007-03-22 Univ Of Yamanashi 止血疾患治療用の医薬組成物

Also Published As

Publication number Publication date
WO2009040002A1 (en) 2009-04-02
CN101809168A (zh) 2010-08-18
JP2010539891A (ja) 2010-12-24
KR20100059897A (ko) 2010-06-04
CA2700219A1 (en) 2009-04-02
ATE547706T1 (de) 2012-03-15
TW200934877A (en) 2009-08-16
BRPI0817944A2 (pt) 2015-05-05
US20100311053A1 (en) 2010-12-09
EP2048243A1 (en) 2009-04-15
SG184704A1 (en) 2012-10-30
IL204557A0 (en) 2010-11-30
EP2195455B1 (en) 2012-02-29
AU2008303866A1 (en) 2009-04-02
AR068529A1 (es) 2009-11-18
EP2233584A1 (en) 2010-09-29
EP2195455A1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
MX2012002076A (es) Deteccion de evento de ariloxialcanoato dioxigenasa-1 das-40278-9.
MX2019008675A (es) Variantes de hidroxiesteroide 17-beta deshidrogenasa 13 (hsd17b13) y usos de estas.
WO2007147074A3 (en) Use of highly parallel snp genotyping for fetal diagnosis
WO2012024535A3 (en) Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd)
EP2569453A4 (en) Nucleic Acid ISOLATION METHOD
WO2006110855A3 (en) Methods for determining sequence variants using ultra-deep sequencing
WO2007076523A3 (en) Markers and methods for assessing and treating psoriasis and related disorders
DK2019872T3 (da) Fremgangsmåde til forudsigelse af modtageligheden over for TNF-blokkere
WO2007146819A3 (en) Methods for identifying and using snp panels
DE602005009702D1 (de) Esr1 und gebärmutterhalskrebs
EP2179025A4 (en) INTEGRATED APPARATUS FOR PERFORMING NUCLEIC ACID EXTRACTION AND DIAGNOSTIC TESTS ON MULTIPLE BIOLOGICAL SAMPLES
NZ590832A (en) Genetic variants for schizophrenia risk assessment
WO2011133949A3 (en) Genetic risk analysis in reward deficiency syndrome
WO2010019550A3 (en) Method of identifying disease risk factors
EP1578952A4 (en) DIRECT SNP DETECTION WITH UNAMPLIFIED DNA
WO2007114986A3 (en) Cooperative probes and methods of using them
WO2008109423A8 (en) Multigene assay to predict outcome in an individual with glioblastoma
ATE548467T1 (de) Verfahren zur identifizierung von biomarkern mit eignung bei der diagnose biologischer zustände
WO2008028031A3 (en) Markers and methods for assessing and treating ulcerative colitis and related disorders using a 43 gene panel
WO2008136989A3 (en) Polymorphisms in genes affecting sod2-related disorders and uses thereof
WO2010138796A3 (en) Methods for assessment and treatment of depression via utilization of single nucleotide polymorphisms analysis
MX2010008374A (es) Enriquecimiento en dos etapas de adn fetal libre de celula en plasma materno.
MX2010002993A (es) Uso de clec1b para la determinacion de riesgo cardiovascular y trombotico.
IN2012DN04901A (es)
EP1829964A4 (en) METHOD OF STUDYING A SEQUENCE OF A GENE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal